Glaxo/Novopharm Zantac infringement argument questioned by three-judge appeals court.
This article was originally published in The Tan Sheet
Executive Summary
GLAXO v. NOVOPHARM: ZANTAC INFRINGEMENT QUESTIONED BY FEDERAL APPEALS COURT in a Jan. 7 oral arguments hearing in Washington, D.C. The three-judge D.C. federal appeals court addressed Glaxo Wellcome's argument that Novopharm's ANDA for generic ranitidine Form 1 is an infringement because of the "possibility" that Novopharm's generic Form 1 product also could contain Form 2, which Glaxo says would violate the firm's patent on Zantac (ranitidine Form 2).